Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Clinical Data

Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 Readout

 March 30, 2026

BioSpace

While tonlamarsen missed one of two co-primary endpoints, Kardigan says the drug has shown a clinically meaningful effect on blood pressure, supporting advancement into Phase 2b.

Clinical DataCardiovascularRead full story

Post navigation

Biogen Bounces Back With FDA Nod for High-Dose Spinal Muscular Atrophy Drug →
← Blackstone closes $6.3B fund for life sciences investing

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com